source
- FDA clears Abbott’s Libre Duo 10-Day sensor to warn of diabetic ketoacidosisThe U.S. Food and Drug Administration has cleared Abbott’s new wearable device that measures both glucose and ketone levels in people with diabetes. The clearance allows the product to be marketed…
- Ambros Therapeutics merges with Werewolf, raises $150M to fund phase 3 trial of rare disease drugAmbros Therapeutics announced an all‑stock reverse merger with Werewolf Therapeutics, accompanied by a $150 million private placement. The transaction will see the combined company operate under th…